The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Intention to treat – who should use ITT?
Open accessAbstract
In the clinical researcher's perfect world every patient entered into a randomised controlled clinical trial (RCT) would satisfy all entry criteria, would complete their allocated treatment as described in the protocol, and would contribute data records which were complete in all respects. In practice it is doubtful if this ideal is ever achieved, and hence strategies have been developed for the analysis of RCTs which seek to protect their inferential basis from consequent biases. Such a strategy is 'intention to treat' (ITT) which is frequently advocated as the preferred approach to analysis. This is particularly so for major trials designed to establish definitively the efficacy and safety of a new medication or medical procedure. Indeed ITT has been endorsed in regulatory guidelines in Europe and the USA (Nordic Council on Medicines, 1989; Food & Drug Administration, 1988). But is ITT always the preferred approach? Can it always be satisfactorily applied? Is it a well-defined and well understood concept? The subject of ITT regularly arouses debate and controversy. In particular the idea that a patient who has been randomised to treatment A, but actually receives treatment B, should be assigned to the group who received A for analysis purposes is totally incomprehensible to some. This controversy is fuelled by the fact that there are a large number of clinical trials, particularly in the early phases of research, for which ITT would indeed be inappropriate. Further fuel is added by the different attitudes to ITT in different research environments it is a constant concern in the later phases of drug regulation, for example, whereas research workers in the Medical Research Council generally show greater flexibility, probably because they are less concerned with satisfying conservative regulatory requirements. It has even been argued that ITT encourages sloppiness 'Whatever we do, give the treatment or not, it is OK since the analysis is by ITT!'. ITT came to prominence in connection with long-term RCTs with mortality as their major end-point. Peto and co-workers laid out the general principles for the design and analysis of such studies in their comprehensive and highly influential publications in this journal (Peto et al., 1976, 1977). They did not use the term 'intention to treat' but did advocate that 'even patients who do not get the proper treatment must not be withdrawn from the analysis'. Their guidance is detailed: the various ways in which patients may fail to complete the study as per protocol are all discussed, together with the possibility that the patients who so fail may differ in characteristics, or numbers, from treatment arm to treatment arm. Such differences are the source of the bias which ITT attempts to avoid any analysis which omits patients is open to bias because it no longer compares the groups as randomised. However, although Peto and coworkers do recommend that all properly randomised patients should be included in the analysis regardless of protocol deviation, they do leave open the possibility for some inappropriately randomised patients to be excluded, and thus stop short of espousing the inclusion of all randomised patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
RUBIN, D. B. (1976) · Biometrika · doi:10.1093/biomet/63.3.581 · Cited by 9,925
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1976) · British Journal of Cancer · doi:10.1038/bjc.1976.220 · Cited by 2,294
Cited by
Moher, D., Hopewell, S., Schulz, K. F., Montori, V., Gotzsche, P. C., Devereaux, P. J., Elbourne, D., Egger, M., & Altman, D. G. (2010) · BMJ · doi:10.1136/bmj.c869 · Cited by 8,883
The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration
Altman, D. G., Schulz, K. F., Moher, D., Egger, M., Davidoff, F., Elbourne, D., Gøtzsche, P. C., Lang, T., & for the CONSORT Group (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-8-200104170-00012 · Cited by 3,835
Philip, T., Guglielmi, C., Hagenbeek, A., Somers, R., Van Der Lelie, H., Bron, D., Sonneveld, P., Gisselbrecht, C., Cahn, J.-Y., Harousseau, J.-L., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512073332305 · Cited by 2,439
Moher, D., Hopewell, S., Schulz, K. F., Montori, V., Gøtzsche, P. C., Devereaux, P. J., Elbourne, D., Egger, M., & Altman, D. G. (2012) · International Journal of Surgery · doi:10.1016/j.ijsu.2011.10.001 · Cited by 2,345
What is meant by intention to treat analysis? Survey of published randomised controlled trials
Hollis, S., & Campbell, F. (1999) · BMJ · doi:10.1136/bmj.319.7211.670 · Cited by 2,160
Intention-to-treat concept: A review
Gupta, S. (2011) · Perspectives in Clinical Research · doi:10.4103/2229-3485.83221 · Cited by 1,921
Moher, D., Hopewell, S., Schulz, K. F., Montori, V., Gøtzsche, P. C., Devereaux, P. J., Elbourne, D., Egger, M., & Altman, D. G. (2010) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.03.004 · Cited by 1,858
Fisher, B., Anderson, S., Redmond, C. K., Wolmark, N., Wickerham, D. L., & Cronin, W. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511303332203 · Cited by 1,465
Delgado-Rodríguez, M., & Llorca, J. (2004) · Journal of Epidemiology and Community Health · doi:10.1136/jech.2003.008466 · Cited by 1,064
Trials to assess equivalence: the importance of rigorous methods: Fig 1
Jones, B., Jarvis, P., Lewis, J. A., & Ebbutt, A. F. (1996) · BMJ · doi:10.1136/bmj.313.7048.36 · Cited by 1,032
“The most difficult issue relating to the analysis of an equivalence trial concerns which patients and which data from these patients to include. The most common approaches to the analysis of randomised trials are “intention to treat” and “per protocol” analyses. A fuller discussion of intention to treat can be found i…”
MethodSelf-citationINTERNATIONALCOLLABORATIVEHYPERT, VERNON, C., HAND, J., FIELD, S., MACHIN, D., WHALEY, J., ZEE, J., VANPUTTEN, W., VANRHOON, G., & VANDIJK, J. (1996) · International Journal of Radiation OncologyBiologyPhysics · doi:10.1016/0360-3016(96)00154-x · Cited by 725
Self-citationSample size slippages in randomised trials: exclusions and the lost and wayward.
Schulz, K. F., & Grimes, D. A. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07882-0 · Cited by 642
A RANDOMIZED ACTIVE-CONTROLLED TRIAL OF MYCOPHENOLATE MOFETIL IN HEART TRANSPLANT RECIPIENTS1
Kobashigawa, J., Miller, L., Renlund, D., Mentzer, R., Alderman, E., Bourge, R., Costanzo, M., Eisen, H., Dureau, G., Ratkovec, R., et al. (1998) · Transplantation · doi:10.1097/00007890-199808270-00016 · Cited by 615
Koumantakis, G. A., Watson, P. J., & Oldham, J. A. (2005) · Physical Therapy · doi:10.1093/ptj/85.3.209 · Cited by 433
Sze, W. M., Shelley, M. D., Held, I., Wilt, T. J., & Mason, M. D. (2003) · Clinical Oncology · doi:10.1016/s0936-6555(03)00113-4 · Cited by 432
Imputing response rates from means and standard deviations in meta-analyses
Furukawa, T. A., Cipriani, A., Barbui, C., Brambilla, P., & Watanabe, N. (2005) · International Clinical Psychopharmacology · doi:10.1097/00004850-200501000-00010 · Cited by 337
Recommendations by Cochrane Review Groups for assessment of the risk of bias in studies
Lundh, A., & Gøtzsche, P. C. (2008) · BMC Medical Research Methodology · doi:10.1186/1471-2288-8-22 · Cited by 352
Fisher, B., Anderson, S., Wickerham, D. L., DeCillis, A., Dimitrov, N., Mamounas, E., Wolmark, N., Pugh, R., Atkins, J. N., Meyers, F. J., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.5.1858 · Cited by 308
Snapinn, S. M. (2000) · Trials · doi:10.1186/cvm-1-1-019 · Cited by 267
Modified intention to treat reporting in randomised controlled trials: systematic review
Abraha, I., & Montedori, A. (2010) · BMJ · doi:10.1136/bmj.c2697 · Cited by 255
Investigating patient exclusion bias in meta-analysis
Tierney, J. F. (2004) · International Journal of Epidemiology · doi:10.1093/ije/dyh300 · Cited by 221
Lactobacillus rhamnosus GG versus Placebo for Acute Gastroenteritis in Children
Schnadower, D., Tarr, P. I., Casper, T. C., Gorelick, M. H., Dean, J. M., O’Connell, K. J., Mahajan, P., Levine, A. C., Bhatt, S. R., Roskind, C. G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802598 · Cited by 208
Abraha, I., Cherubini, A., Cozzolino, F., De Florio, R., Luchetta, M. L., Rimland, J. M., Folletti, I., Marchesi, M., Germani, A., Orso, M., et al. (2015) · BMJ · doi:10.1136/bmj.h2445 · Cited by 165
Intention-to-treat approach to data from randomized controlled trials: a sensitivity analysis
Wright, C. C., & Sim, J. (2003) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(03)00155-0 · Cited by 171
Schulz, K. F., Grimes, D. A., Altman, D. G., & Hayes, R. J. (1996) · BMJ · doi:10.1136/bmj.312.7033.742 · Cited by 163
SUMATHIPALA, A., HEWEGE, S., HANWELLA, R., & MANN, A. H. (2000) · Psychological Medicine · doi:10.1017/s0033291799002160 · Cited by 129
Elkins, M. R., & Moseley, A. M. (2015) · Journal of Physiotherapy · doi:10.1016/j.jphys.2015.05.013 · Cited by 122
Therapeutic equivalence: fallacies and falsification
Garrett, A. D. (2003) · Statistics in Medicine · doi:10.1002/sim.1360 · Cited by 88
(2002) · PubMed · Cited by 74
The role of intention to treat in analysis of noninferiority studies
Wiens, B. L., & Zhao, W. (2007) · Clinical Trials · doi:10.1177/1740774507079443 · Cited by 72
“Some authors have stated that PP and ITT form extremes; if both yield the same conclusion, there can be some level of comfort that the choice of analysis set does not have a meaningful impact on the conclusions [19,12].”
BackgroundJoseph, R., Sim, J., Ogollah, R., & Lewis, M. (2015) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2014.09.002 · Cited by 50
Findings From a Real-World Translation Study of the Evidence-Based “Partners in Dementia Care”
Bass, D. M., Hornick, T., Kunik, M., Judge, K. S., Primetica, B., Kearney, K., Rentsch, J., Mccarthy, C., & Grim, J. (2019) · Innovation in Aging · doi:10.1093/geroni/igz031 · Cited by 32
Impact of missing data on type 1 error rates in non-inferiority trials
Yoo, B. (2010) · Pharmaceutical Statistics · doi:10.1002/pst.378 · Cited by 12
Metadata
- Authors
- Lewis, J., & Machin, D.
- Venue
- British Journal of Cancer
- Published
- 1993-10-01
- Volume
- 68
- Issue
- 4
- Pages
- 647-650
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2044763202
- Cited by
- 235
- References
- 3
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.